晚期乳腺癌患者需要新型治疗。已开发新的潜在治疗方法，如养护细胞疗法和其他无细胞免疫疗法。本研究的目的是评估三种患者衍生免疫组分，包括CTL、NK细胞和NK衍生EVs的细胞毒性，并评估发展新型乳腺癌治疗的潜力。 CTLs被激活反对MUC-1抗原。采用流式细胞术评估三种成分的体外细胞毒性，体内研究显示了养护细胞疗法的疗效。 总体而言，CTLs对MCF7乳腺腺癌球的细胞毒性最高，在所有情况下均高于NK细胞的细胞毒性。与这两种细胞群相比，NK来源的EV 对MCF7乳腺癌球影响最小。 MUC-1 特异性的CTLs通过养护细胞疗法小鼠研究进行评估，并显示出良好的耐受性和适度的疗效。需要更多的研究来评估CTLs的安全性和疗效，以评估它们的临床潜力，而NK细胞和NK来源的EVs是有前途的候选者，需要进行更多的实验以增强它们的细胞毒性。 版权所有©2023美国组织相容性和免疫遗传学学会。由Elsevier Inc.出版。保留所有权利。

Patients with advanced stage breast cancer need novel therapies. New potential treatments have been developed, such as adoptive cellular therapies and alternative cell-free immunotherapies. The goal of this study was to assess the cytotoxicity of three of the patient-derived immune components, CTLs, NK cells and NK-derived EVs, and evaluate the potential for the development of novel therapy against breast cancer. CTLs were activated against MUC-1 antigen. The in vitro cytotoxic activity of three components was assessed with flow cytometry and in vivo study revealed the efficacy of adoptive cell therapy. Overall, CTLs exhibited the highest cytotoxicity against spheroids of MCF7 breast adenocarcinoma, reaching in all cases higher than double the percentage of NK cells' cytotoxicity. NK-derived EVs exhibited the lowest effect against MCF7 spheroids comparing to the two cell populations. MUC-1 specific CTLs were evaluated with adoptive cell therapy mice study and appeared to be well tolerable and moderately efficacious. More studies need to be performed with CTLs to evaluate safety and efficacy in order to assess their clinical potential, while NK cells and NK-derived EVs are promising candidates that require more experiments to enhance their cytotoxicity.Copyright © 2023 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.